Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), TransMedics Group (TMDX) and Arcus Biosciences (RCUS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on MiMedx Group (MDXG – Research Report), TransMedics Group (TMDX – Research Report) and Arcus Biosciences (RCUS – Research Report).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MiMedx Group (MDXG)
In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on MiMedx Group, with a price target of $12.00. The company’s shares closed last Wednesday at $7.19.
According to TipRanks.com, Takkinen is a 3-star analyst with an average return of
MiMedx Group has an analyst consensus of Strong Buy, with a price target consensus of $12.00.
See the top stocks recommended by analysts >>
TransMedics Group (TMDX)
Morgan Stanley analyst Patrick Wood maintained a Hold rating on TransMedics Group today and set a price target of $123.00. The company’s shares closed last Wednesday at $134.32.
According to TipRanks.com, Wood is a 1-star analyst with an average return of
TransMedics Group has an analyst consensus of Strong Buy, with a price target consensus of $144.50.
Arcus Biosciences (RCUS)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on Arcus Biosciences today and set a price target of $23.00. The company’s shares closed last Wednesday at $20.29.
According to TipRanks.com, Flynn is a 4-star analyst with an average return of
Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $31.50, representing a 57.5% upside. In a report issued on October 20, Wells Fargo also maintained a Buy rating on the stock with a $29.00 price target.
Read More on MDXG:
